Home Guides Tirzepatide Dosage Chart 2026
Tirzepatide Dosage Chart 2026: The Full Titration Schedule (2.5 mg → 15 mg)
Tirzepatide starts at 2.5 mg once weekly and steps up by 2.5 mg no sooner than every four weeks, through 5, 7.5, 10, 12.5 and 15 mg. The 2.5 mg starter dose is not a treatment dose — it exis…
Tirzepatide starts at 2.5 mg once weekly and steps up by 2.5 mg no sooner than every four weeks, through 5, 7.5, 10, 12.5 and 15 mg. The 2.5 mg starter dose is not a treatment dose — it exists to build gastrointestinal tolerance. Most people see the bulk of their results between 7.5 mg and 12.5 mg, and many never need 15 mg.
On this page
The schedule, week by week
The label schedule is deliberately slow. You stay at 2.5 mg for four weeks, then move to 5 mg for at least four weeks, and continue in 2.5 mg steps with a minimum of four weeks at each new dose. There is no clinical reason to move faster, and moving faster is the single most common cause of the nausea that makes people quit.
Weeks 1–4 sit at 2.5 mg. This dose produces little weight loss for most people and that is expected — its job is to let the gut adapt. Weeks 5–8 at 5 mg is where appetite suppression usually becomes obvious. From week 9 onward, each step is a judgment call between more effect and more side effects.
Your prescriber can hold you at any dose indefinitely. If 7.5 mg is producing steady loss with tolerable side effects, there is no requirement to climb. Escalation is a tool for an inadequate response, not a schedule you owe anyone.
What each dose actually does
In SURMOUNT-1, mean 72-week weight loss was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg. The gap between 10 mg and 15 mg is small — roughly 1.4 percentage points — while side effects and, on dose-scaled pricing, cost both continue to climb. That flattening is why 10 mg is the most common long-term maintenance dose in practice.
If you have type 2 diabetes, scale your expectations down. SURMOUNT-2 found 12.8% at 10 mg and 14.7% at 15 mg in that population — real, meaningful, but roughly two-thirds of the non-diabetic figures.
Missed doses
If you remember within four days (96 hours) of your scheduled day, take it and keep your original weekly schedule. If more than four days have passed, skip it entirely and take the next dose on your normal day. Never take two doses within three days of each other.
If you miss more than one consecutive week, contact your prescriber before resuming. Tolerance to gastrointestinal effects fades quickly, and restarting at your previous dose after a long gap is a common cause of severe nausea. Many clinicians will step you back down a level and re-titrate.
The cost trap hidden in the schedule
Titration is where dose-scaled pricing bites. A program advertising a low entry price is often quoting the 2.5 mg tier — the dose you occupy for exactly four weeks. By the time you reach the dose that is actually working for you, that same program may be charging substantially more per month.
Flat-rate programs charge one price at every tier. Over a 12-month course that difference typically dwarfs any first-month discount. Run your own numbers on the price calculator before you commit to anything.
Common questions
What dose of tirzepatide do most people end up on?
Most people settle between 7.5 mg and 12.5 mg. The efficacy gain from 10 mg to 15 mg was only about 1.4 percentage points in SURMOUNT-1, while side effects and often price continue to rise. Many people never need 15 mg.
Why do tirzepatide prices go up as my dose increases?
Because some programs price by dose tier rather than charging one rate. The advertised price usually reflects the 2.5 mg starter dose, which you occupy for about four weeks. Flat-rate programs charge the same amount at every dose. Over twelve months that structural difference typically matters more than any first-month discount.
What happens if I stop taking tirzepatide?
Weight regain is expected. In SURMOUNT-4, participants who switched to placebo after 36 weeks regained 14% of body weight over the following year, while those who continued lost a further 5.5%. Obesity behaves as a chronic condition and treatment is generally open-ended.
Is compounded tirzepatide legal in 2026?
Yes, when a state-licensed 503A pharmacy prepares it for an identified individual patient with a valid prescription. FDA declared the tirzepatide shortage resolved in December 2024, which ended mass compounding under shortage rules. Patient-specific compounding under section 503A of the Federal Food, Drug, and Cosmetic Act continues.
People also ask about tirzepatide dosage chart
What is tirzepatide dosage chart?
Tirzepatide dosage chart is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide dosage chart apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide dosage chart cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide dosage chart FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.